Souhaitez-vous accéder aux communiqués récents ?

The multicenter, open-label study will enroll up to 50 patients with advanced solid tumors, including pancreatic, ovarian, and refractory prostate cancers

Propanc believes this non-cytotoxic, differentiation-based approach addresses key drivers of resistance, recurrence, and dissemination that persist

The world-first clinical study is a Phase 1b, open‑label, dose escalation and dose expansion study of PRP in patients with advanced solid tumors.

Further improvements can be made with complementary treatment modalities such as PRP that target the way cancer cells become malignant, invasive and spread

The data reinforces PRP’s differentiated mechanism targeting cancer stem cells, disrupting fibrotic microenvironment, and potentially overcoming resistance

We feel strongly about undertaking important corporate actions that reflect the true value of our shareholders’ equity

A synthetic recombinant PRP is the next phase of our strategic plan in building a new therapeutic drug class aimed at treating a range of chronic diseases

Both parties intend to approach the collaboration in a spirit of openness, scientific rigor, and shared problem-solving, with the goal of advancing PRP

"We feel strongly about undertaking important corporate actions that reflect the true value of our shareholders’ equity."

"Visting our CDMO partner provides tremendous benefits being able to visualize future cGMP production of PRP"